Table 2. Phenotype and genotype of the ErPCs from thalassemia patients employed in microRNA-210 and raptor analyses.
Patient number | α-globin mRNA (*) | β-globin mRNA (*) | γ-globin mRNA (*) | genotype |
---|---|---|---|---|
1 | 1.26 | 0.74 | 10.70 | β0-39/β+-IVSI-110 |
2 | 1.27 | 1.14 | 5.13 | β0-IVSI-1/β+-IVSI-6 |
3 | 0.72 | 2.05 | 1.80 | β0-39/β0–39 |
4 | 1.09 | 0.95 | 2.14 | β0-39/β0–39 |
5 | 1.11 | 0.96 | 3.05 | β+-IVSI-6/β+-IVSI-110 |
6 | 1.04 | 1.13 | 3.39 | β0-39/β+-IVSI-110 |
7 | 1.71 | 0.97 | 3.80 | β0-39/β0–39 |
8 | 0.29 | 0.17 | 2.39 | β0-39/β0-IVSI-6 |
9 | 1.13 | 2.35 | 4.29 | β0-6(-A)/β+-IVSI-110 |
(*) fold increase in MTH-treated Th-ErPCs (with respect to untreated control cells)